ABSTRACT OF THE DISCLOSURE

The present invention relates to epilepsy [illegible] The present invention relates to idiopathic generalized epilepsy (IGE), and to the identification of three genes mapping to chromosome 8 which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences and protein sequences [illegible] IGE[illegible] and to the use thereof to assess the prognosis or treatment to predict an epileptic individual's response to medication and to identify agents which modulate the function of [illegible] SCN1A. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A with an identified compound which have therapeutic benefit for epilepsy or related neurological disorders.